Edition:
India

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

35.71USD
20 Sep 2019
Change (% chg)

$0.07 (+0.20%)
Prev Close
$35.64
Open
$35.82
Day's High
$35.95
Day's Low
$35.70
Volume
845,123
Avg. Vol
1,043,973
52-wk High
$35.95
52-wk Low
$25.10

Select another date:

Tue, Sep 3 2019

Photo

Roche, Spark again extend $4.3 billion takeover offer

ZURICH Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.

Roche, Spark again extend $4.3 billion takeover offer

ZURICH Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.

Roche, Spark again extend $4.3 bln takeover offer

ZURICH, Sept 3 Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.

Roche taps Lilly executive Garraway as chief medical officer

ZURICH Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

UPDATE 1-Roche taps Lilly executive Garraway as chief medical officer

ZURICH, Aug 19 Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Roche taps Eli Lilly executive as chief medical officer

ZURICH, Aug 19 Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.

UPDATE 2-Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Aug 16 Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.

Roche personalized cancer treatment to cost about $204,560 a year

Roche Holding AG has priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, that targets tumors with specific genetic mutations, the Swiss drugmaker said.

Roche prices personalized cancer treatment at about $204,560 annually

Aug 16 Roche Holding AG priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, which targets tumors with specific genetic mutations, the Swiss drugmaker said.

Select another date: